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Abstract
Background: Kinin B1 receptor (B1R) is induced by the oxidative stress in models of diabetes mellitus. This study aims at
determining whether B1R activation could perpetuate the oxidative stress which leads to diabetic complications.
Methods and Findings: Young Sprague-Dawley rats were fed with 10% D-Glucose or tap water (controls) for 8–12 weeks. A
selective B1R antagonist (SSR240612) was administered acutely (3–30 mg/kg) or daily for a period of 7 days (10 mg/kg) and
the impact was measured on systolic blood pressure, allodynia, protein and/or mRNA B1R expression, aortic superoxide
anion (O2
N2) production and expression of superoxide dismutase (MnSOD) and catalase. SSR240612 reduced dose-
dependently (3–30 mg/kg) high blood pressure in 12-week glucose-fed rats, but had no effect in controls. Eight-week
glucose-fed rats exhibited insulin resistance (HOMA index), hypertension, tactile and cold allodynia and significant increases
of plasma levels of glucose and insulin. This was associated with higher aortic levels of O2
N2, NADPH oxidase activity, MnSOD
and catalase expression. All these abnormalities including B1R overexpression (spinal cord, aorta, liver and gastrocnemius
muscle) were normalized by the prolonged treatment with SSR240612. The production of O2
N2 in the aorta of glucose-fed
rats was also measured in the presence and absence of inhibitors (10–100 mM) of NADPH oxidase (apocynin), xanthine
oxidase (allopurinol) or nitric oxide synthase (L-NAME) with and without Sar[D-Phe
8]des-Arg
9-BK (20 mM; B1R agonist). Data
show that the greater aortic O2
N2 production induced by the B1R agonist was blocked only by apocynin.
Conclusions: Activation of kinin B1R increased O2
N2 through the activation of NADPH oxidase in the vasculature. Prolonged
blockade of B1R restored cardiovascular, sensory and metabolic abnormalities by reducing oxidative stress and B1R gene
expression in this model.
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Introduction
Recent evidence suggests a link between insulin resistance,
oxidative stress, pain polyneuropathy and the overexpression of
kinin B1 receptor [1,2,3]. Kinins are vasoactive peptides and pro-
inflammatory pain mediators which act through the activation of
two G-protein-coupled receptors (R), named B1 and B2.W h i l e
the B1R has a low level of expression in healthy subjects, it is
induced and overexpressed after exposure to pro-inflammatory
cytokines, bacterial endotoxins and hyperglycaemia-induced
oxidative stress [4,5]. Bradykinin (BK) and Lys-BK are the
natural agonists for the constitutive B2R, while the kininase I
metabolites des-Arg
9-BK and Lys-des-Arg
9-BK are the selective
agonists for the B1R[ 6 ] .
Autoradiographic and molecular studies showed an increased
density of B1R binding sites and mRNA in the brain, spinal cord
and peripheral tissues of rats treated with D-Glucose (10% in
drinking water) for a period of 4 and 12 weeks [2,3,7]. Glucose-fed
rats displayed higher plasma levels of glucose and insulin, insulin
resistance, arterial hypertension, enhanced production of super-
oxide anion (O2
N2) in the heart and aorta [8,9,10] and pain
polyneuropathy as assessed by the presence of tactile and cold
allodynia [1,2,3]. Recently, we reported that all these abnormal-
ities including B1R overexpression were reduced with a diet
containing alpha-lipoic acid or N-Acetyl-L-Cysteine, two potent
antioxidants [2,3], supporting a link between the upregulation of
B1R, diabetic complications and the oxidative stress. An acute
treatment with B1R antagonists (LF22-0542, SSR240612 and R-
715) reversed tactile and cold allodynia in high glucose feeding
[1,2]. However, only the brain penetrant B1R antagonist (LF22-
0542) and not the peripherally acting R-715 decreased high
systolic blood pressure in glucose-fed rats [2].
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12622The present study was undertaken to determine the beneficial
effect of a prolonged treatment (1 week) with the centrally and
peripherally acting B1R antagonist SSR240612 on the main
features and complications of diabetes in high glucose feeding. It is
hypothesised that activation of B1R increases oxidative stress
(aortic O2
N2) and that its prolonged inhibition reverses oxidative
stress and the subsequent upregulation of B1R which is responsible
for arterial hypertension and pain polyneuropathy. The source of
O2
N2 was identified with the use of specific inhibitors of oxidative
enzymes. The status of the antioxidant defence was determined by
measuring the vascular expression of two selected antioxidant
enzymes, superoxide dismutase (MnSOD) and catalase. MnSOD
metabolises O2
N2 to hydrogen peroxide which is converted to
water by catalase. The data highlight a detrimental role for B1Ri n
diabetes through a mechanism involving the oxidative stress and
NADPH oxidase.
Materials and Methods
Animals and Procedures
Young male Sprague-Dawley rats (24–28 days old weighting
50–75 g, Charles River Laboratories, St-Constant, Quebec,
Canada) were housed two per cage, under controlled conditions
of temperature (22uC) and humidity (43%), on a 12-hour light-
dark cycle and allowed free access to normal chow diet and tap
water (control rats) or 10% D-glucose in the drinking water during
8 or 12 weeks for chronic and acute studies, respectively All
research procedures and the care of the animals were in
compliance with the guiding principles for animal experimentation
as enunciated by the Canadian Council on Animal Care and were
approved by the Animal Care Committee of our University
(CDEA approval ID: 09-066).
Acute effect of SSR240612 on blood pressure
A first series of experiments was performed in 12-week glucose-
fed rats to assess the acute effects of several doses of SSR240612 on
systolic blood pressure in order to select the optimal dose for
chronic experiment. SSR240612 was administered by gavage at
doses of 3, 10 and 30 mg/kg and effects were measured up to 48 h
post-administration in unanaesthetized rats. At the end of this
protocol, rats were euthanized by CO2 inhalation. Doses were
selected on the basis of previous studies performed in various in
vivo models of inflammation, pain and diabetes in rats and mice
[11,12,13]. Moreover, these doses of SSR240612 were found
appropriate to block acutely allodynia in the model of glucose-fed
rats [1].
Chronic effect of SSR240612 on blood pressure, allodynia
and other parameters
These studies were carried out in 4 groups of 8-week glucose
feeding and control rats (diabetic and control 6 vehicle, diabetic
and control 6 SSR240612). The dose of 10 mg/kg SSR240612
was selected for the chronic study on the basis of the dose-response
curve constructed on blood pressure (present study) and allodynia
[1]. This dose was administered by gavage once a day in the
morning for one week in control rats and in rats fed with D-
Glucose. Thus, effects of 10 mg/kg of SSR240612 were
determined on allodynia and arterial hypertension at 0 h, 3 h,
6 h, 24 h, 48 h, 72 h, 96 h, 120 h, 144 h and 168 h post-gavage.
On day 7, overnight-fasted rats were anaesthetized and then
euthanized by CO2 inhalation, 3 h after the last treatment with
SSR240612, to collect tissues and blood samples for biochemical
and molecular studies.
Measurement of plasma glucose, insulin and insulin
resistance
At the end of protocol, overnight-fasted rats were slightly
anaesthetized with CO2 inhalation and blood was rapidly collected
from sectioned carotid arteries and immediately transferred into a
chilled tube of 6 ml containing 10.8 mg EDTA. The plasma was
obtained by centrifugation and kept frozen at 220uC for the later
measurement of glucose with a glucometer Accu-Chek (Roche
Diagnostics Inc, Laval, Quebec, Canada) and insulin by
radioimmunoassay (rat insulin RIA kit, Linco Research, St
Charles, MO, USA) using 100 ml of plasma. The Homeostasis
Model Assessment index (HOMA) was used as an index of insulin
resistance and calculated with the following formula: [insulin (mU/
ml) x glucose (mM)/22.5] [14].
Measurement of systolic blood pressure
Systolic arterial blood pressure was measured by tail-cuff
plethysmography (Harvard Apparatus Ltd, Kent, UK) with the
use of a cuff placed around the tail and registered on a MacLab/8
system. For each measurement, three individual readings were
averaged [2,3].
Measurement of Allodynia
Tactile and cold allodynia were assessed with the rats placed on
a wire mesh floor beneath an inverted plastic cage. The rats were
allowed to adapt for about 15 min or until explorative behaviour
ceased. Tactile allodynia was assessed by measuring the hindpaw
withdrawal threshold to the application of a calibrated series of six
von Frey filaments (bending forces of 2, 4, 6, 8, 10 and 15 g)
applied perpendicularly to the mid-plantar surface as described
previously [1,2,3]. Cold allodynia was assessed using the acetone
drop method applied to the plantar surface of the hindpaws as
previously described [1,2,3]. The frequency of paw withdrawal
was expressed as a percentage (the number of paw withdrawals 4
number of trials 6100).
Measurement of superoxide anion and NADPH oxidase
activity in the aorta
Superoxide anion (O2
N2) production was measured in frozen
isolated thoracic aorta rings using the lucigenin-enhanced
chemiluminescence method as described previously [15,16].
Briefly, isolated aortas cut in 2–5 mm rings were pre-incubated
at 37uC for 30 min in Krebs-HEPES buffer (saturated with 95%
O2 and 5% CO2). Aortic rings were then transferred in duplicate
to glass scintillation vials containing 200 ml of lucigenin (5 mM),
which was previously dark adapted for 30 min. The chemilumi-
nescence was recorded every minute for 10 min at room
temperature using a liquid scintillation counter (Wallac 1409;
Perkin Elmer Life Science, St Laurent, Quebec, Canada).
Lucigenin counts were expressed as counts per minute per
milligram of dry weight tissue (cpm/mg). The estimation of
NADPH oxidase activity was achieved by adding to the aorta vials
NADPH (10
24 M) before counting for another 6 min. Basal
superoxide-induced luminescence was subtracted from the lumi-
nescence value induced by NADPH. Background counts were
determined from vessel-free incubation media containing lucigenin
and subtracted from the readings obtained with vessels.
Experiments designed to study the source of O2
N2 were carried
out as indicated above in freshly isolated aorta with the addition of
vehicle or one of the following inhibitors: N
v-nitro-L-arginine
methyl ester (L-NAME,100 mM, nitric oxide synthase inhibitor)
[17], allopurinol (100 mM, xanthine oxidase inhibitor) [16],
apocynin (10 mM, NADPH oxidase inhibitor) [18]. One hour
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8]des-Arg
9-BK (20 mM) [19] was
added to the solution for a further period of 15 min. In vivo
experiments were also carried out in glucose-fed rats in which the
B1R agonist Sar[D-Phe
8]des-Arg
9-BK (1 mg/kg, i.p.) was admin-
istered 30 min after apocynin (50 mg/kg, i.p.). After a systemic
exposure of 30 min to the B1R agonist or its vehicle, rats were
sacrificed under CO2 inhalation, the aortas isolated and processed
for O2
N2 measurement as indicated above.
The in situ level of O2
N2 in the aorta was also evaluated by the
oxidative fluorescent dye dihydroethidine as described earlier [20].
Cells are permeable to dihydroethidine and, in the presence of
O2
N2, it is oxidized to fluorescent ethidium bromide (EtBr) which is
trapped by intercalation with DNA. EtBr is excited at 518 nm
with an emission spectrum of 605 nm. Unfixed frozen aorta
segments from the four experimental groups of rats (4 controls, 4
controls + SSR240612, 4 glucose-treated, 4 glucose-treated +
SSR240612) were cut into 20-mm thick sections and placed on
glass slides. Dihydroethidine (2 mM) was applied to tissue sections
and coverslipped. The slides were then incubated in a light-
protected humidified chamber at 37uC for 30 min. Images were
obtained with a Leica TCS SP confocal microscope equipped with
an argon laser (Leica microsystem Co., Germany). Tissues from
the four groups were processed and imaged in parallel. Laser
settings were identical for acquisition of images from all sections.
Computer based analysis was performed with Image J software
and calculated by the following equation: I=g I/(A/N), where I
is the fluorescence intensity, g I is the summation of all nuclei
intensity, A is the total area of the nuclei, and N is the number of
nuclei used. Data are expressed as an average of total nuclei
fluorescence quantified in triplicate of 4 rats.
Real-time quantitative polymerase chain reaction (qRT-
PCR)
Once the blood was collected after sacrifice, approximately
10 mg of each isolated tissue (thoracic aorta and spinal cord, liver,
gastrocnemius muscle) were put in RNAlater stabilisation reagent
(QIAGEN, Valencia, CA, USA). Total RNAs were extracted from
tissue according to the manufacturer’s instructions. First-strand
cDNA synthesized from 400 ng total RNA with random hexamer
primers was used as template for each reaction with the
QuantiTect Rev Transcription Kit (QIAGEN). qRT-PCR was
performed in SYBR Green Master mix (QIAGEN) with 300 nM
of each primer and signal detected using a Mx3000p device
(Stratagene, La Jolla, CA, USA) as described [21]. For
standardization and quantification, rat 18S was amplified
simultaneously. The primer pairs were designed by Vector NTI
software (Table 1).
PCR conditions were: 95uC for 15 min, followed by 46 cycles at
94uC for 15 s, 60uC for 30 s and 72uC for 30 s. The cycle
threshold (Ct) value represents the cycle number at which a
fluorescent signal rises statistically above background [22]. The
relative quantification of gene expression was analyzed by the
2
2DDCt method [23].
Density and distribution of kinin B1 receptors by
autoradiography
After sacrifice of rats, part of the thoracic spinal cord (T3–T7)
was immediately frozen in 2-methylbutane cooled at 245 to
255uC with liquid nitrogen and kept at 280uC. Spinal cords were
mounted in a gelatine block, serially cut into 20 mm thick coronal
sections on a cryostat and stored at 280uC for 1 month.
Thereafter sections were thawed at room temperature, pre-
incubated for 10 min in 25 mM PIPES-NH4OH buffer (pH 7.4)
and then incubated at room temperature for 90 min in the same
buffer containing peptidase inhibitors and 200 pM of [
125I]-HPP-
desArg
10-Hoe 140 [2,3,24]. The non-specific binding was
determined in the presence of 1 mM of the B1 receptor antagonist:
R715 (AcLys[D-ßNal
7,Ile
8]des-Arg
9-BK [6]. Kodak Scientific
Imaging Films BIOMAX
TM MRH (Amersham Pharmacia Biotech
Canada) were juxtaposed onto the slides in the presence of [
125I]-
microscales and exposed at room temperature for 5–7 days.
Autoradiograms were quantified by densitometry using an
MCID
TM image analysis system. A standard curve from [
125I]-
microscales was used to convert density levels into fentomoles per
milligram of protein [25]. Specific binding was determined by
subtracting values of non-specific binding from that of total
binding. Total binding and non-specific binding were measured
separately on 4 sections per rat with 6–8 rats per group.
Western blot analysis
Western blot analysis of protein expression was performed as
described earlier [26]. After sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE), the separated proteins
were electrophoretically wet transferred to a nitrocellulose
membrane (Bio-Rad) at 100 V for 1 h. After transfer, the
membranes were washed twice in PBS-Tween 20 and incubated
in PBS containing 5% skim milk at room temperature for 1 h. The
blots were cut in pieces according to the molecular weight of the
protein and then incubated with the specific antibodies for
MnSOD (1/500, cat number: sc-18503), catalase (1/500, cat
number: sc-34285), dynein (1/5000, cat number: sc-13524) and b-
actin (1/10000, cat number A5441) in PBS-Tween 20 at 4uC
overnight. Dynein and b-actin were used as standard proteins.
After three washings in PBS-Tween 20 buffer, the membranes
were incubated for 1 h at room temperature in PBS-Tween 20
containing 5% milk with secondary antibody that is bovine anti-
goat IgG-HRP (1/5000, cat number: sc-2350) or anti-mouse IgG-
HRP (1/5000, cat number sc-2005) (for b-actin and dynein). b-
Table 1. Primer pairs used in qRT-PCR analysis.
Gene Sequences Position Gen Bank
B1 receptor forward 59GCA GCG CTT AAC CAT AGC GGA AAT 39 367–391 NM_030851
B1 receptor reverse 59CCA GTT GAA ACG GTT CCC GAT GTT 39 478–454 NM_030851
18S forward 59TCA ACT TTC GAT GGT AGT CGC CGT 39 363–386 X01117
18S reverse 59TCC TTG GAT GTG GTA GCC GTT TCT 39 470–447 X01117
MnSOD forward 59ACG CGA CCT ACG TGA ACA ATC TGA 39 175–198 Y00497
MnSOD reverse 59TCC AGC AAC TCT CCT TTG GGT TCT 39 367–344 Y00497
doi:10.1371/journal.pone.0012622.t001
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other antibodies were from Santa Cruz Biotechnology, CA, USA.
The blots were then washed three times with PBS-Tween 20
before the reaction with enhanced-chemiluminescence, Western
blotting detection reagents (Amersham). A quantitative analysis of
the protein was performed by densitometric scanning of the
autoradiographs employing the enhanced laser densitometer, LKB
Ultroscan XL, and quantified using the gel-scan XL evaluation
software (version 2.1) from Pharmacia (Baie d’Urfe ´, Quebec,
Canada).
Drugs
The selective non-peptide B1R antagonist SSR240612 ((2R)-2-
[((3R)-3-(1,3-benzodioxol-5-yl)-3-{[(6-methoxy-2-naphtyl)sulfonyl]
amino}propanoyl)amino]-3-(4-{[(2R,6S)-2,6-dimethylpiperidinyl]
methyl}phenyl)-N-isopropyl-N-methylpropanamide,fumarate) was
obtained from Sanofi-Aventis R&D (Montpellier, France) [12].
Sar[D-Phe
8]des-Arg
9-BK and HPP-des-Arg
10-Hoe140 (3-(4hydro-
xyphenyl)propionyl-desArg
9-D-Arg
0[Hyp
3,Thi
5,D-Tic
7,Oic
8]Brady-
kinin) were synthesized at the Research Institute of Biotechnology,
National Research Council of Canada (Montreal, Quebec, Canada).
R-715 was kindly provided by Dr D. Regoli (Pharmacology,
University of Ferrara, Italy). Iodination of HPP-des-Arg
10-Hoe140
was performed with the chloramine T method as described earlier
[24]. SSR240612 was dissolved in dimethyl sulfoxide (DMSO, 0.5%
v/v) and then ethanol (5% v/v) and Tween-80 (5% v/v) were added
in this sequence. The solution was completed in distilled water. The
drugwas administeredorally by gavagein avolumeof1 mlper 100 g
of body weight. D-Glucose, apocynin, allopurinol, NADPH,
lucigenin and L-NAME were purchased from Sigma-Aldrich
Canada. Dihydroethidine was obtained from Molecular Probes
(Invitrogen Corporation, Carisbad, CA, USA) and suspended in
DMSO at a concentration of 10
23 M, and stored at 220uCu n t i lu s e .
Subsequent dilutions were made in PBS. All other chemicals used
were purchased from standard commercial suppliers and were of
analytical grade.
Statistical analysis of data
Data are expressed as mean 6 s.e.m of values obtained from (n)
rats in each group. Statistical analysis of data was calculated with
GraphPad Prism (version 4.00) software. Statistical differences
were evaluated with Student’s t-test on unpaired samples (B1R
binding sites). Multiple comparisons were analysed using one-way
or two-way analysis of variance (ANOVA), followed by the
Bonferroni post-test. Only probability values (P) less than 0.05
were considered to be statistically significant.
Results
Acute effect of SSR240612 on systolic blood pressure
Systolic blood pressure was significantly increased (P,0.001,
n=6–12) in the four groups of 12-week glucose-treated rats when
compared to control rats and was dose-dependently reduced by
the oral administration of SSR240612 (Baseline values of Glucose
+ vehicle: 151.265.7 mmHg; Glucose + SSR240612 (3 mg/kg):
152.262.0 mmHg; Glucose + SSR240612 (10 mg/kg): 160.46
3.2 mmHg;Glucose + SSR240612(30 mg/kg):156.564.7 mmHg;
Control + SSR240612 (10 mg/kg): 125.363.3 mmHg; Control +
SSR240612 (30 mg/kg): 129.761.9 mmHg) (Figure 1A). When the
area under the curve was measured between 0 h to 48 h post-
administration, the dose of 3 mg/kg did not reach statistical
significance. However, doses of 10 and 30 mg/kg SSR240612
decreased significantly high blood pressure when compared
with vehicle (P,0.05). In contrast, doses of 10 and 30 mg/kg
Figure 1. Acute effect of orally administered SSR240612 on
systolic blood pressure in 12-week glucose-fed rats. Doses of
10 mg/kg and 30 mg/kg of SSR240612 were given to control rats and
doses of 3, 10, 30 mg/kg of SSR240612 or vehicle were given to
glucose-fed rats. Data are mean 6 s.e.m of values obtained from (n) rats
and represent changes of systolic blood pressure in mmHg (A) or Area
Under the Curve (B). Statistical comparison with vehicle (V) in glucose-
fed rats (+) is indicated by + P, 0.05.
doi:10.1371/journal.pone.0012622.g001
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systolic blood pressure (Figure 1B). Therefore, the dose of 10 mg/kg
SSR240612 was selected for chronic treatment in the remainder of
the study.
Chronic effect of SSR240612 on systolic blood pressure
As shown in figure 2, systolic blood pressure was significantly
higher (P,0.001) in glucose-fed rats when compared to age-
matched control rats. A one-week treatment with SSR240612
(10 mg/kg) reduced significantly high blood pressure in glucose-
fed rats at 6 h on day 0 and during the remaining period of
treatment when compared to age-matched glucose-fed rats
receiving the vehicle. The reduction of blood pressure was
incomplete during the premier 2 days of treatment but became
sustained and reached control values from day 3 to day 7. In
contrast, the same treatment with SSR240612 for a period of one
week had no significant effect on systolic blood pressure in control
rats when compared to untreated control rats.
Chronic effect of SSR240612 on allodynia
As shown in figure 3A, glucose-fed rats displayed significant
and sustained tactile allodynia (P,0.001) when compared to
age-matched control rats from day 0 to day 7. Chronic
treatment with 10 mg/kg SSR240612 caused a significant
reduction of tactile allodynia in glucose-fed rats at 3 and 6 h
post-gavage on day 0 when compared to glucose-fed rats treated
with vehicle. The inhibition was entirely reversible at 24 h but
not on the subsequent days until the completion of the
treatment on day 7. The higher paw withdrawal threshold
occurring between day 3 to day 7 in glucose-fed rats treated
with SSR240612 was not significantly different from control
values. Finally, daily administration of 10 mg/kg SSR240612
for 7 days had no significant effect on paw-withdrawal thres-
hold to tactile stimulation in control rats when compared to
untreated control rats.
As shown in figure 3B, glucose-fed rats also displayed significant
cold allodynia (P,0.001) when compared to age-matched control
rats from day 0 to day 7. Significant reduction of cold allodynia
was seen at 3 and 6 h after treatment with 10 mg/kg SSR240612
on day 0 when compared to glucose-fed rats treated with vehicle.
This inhibition was no longer significant at 24 h. On the following
days, daily treatment with SSR240612 led to a striking and
irreversible inhibition of cold allodynia. From day 2 to day 7,
response frequency to cold stimulation was not significantly
different between control and glucose-fed rats treated with
SSR240612. In contrast, the same treatment with SSR240612
for one week had no significant effect on paw-withdrawal
threshold to cold stimulation in control rats when compared to
untreated control rats.
Chronic effect of SSR240612 on various parameters
As shown in table 2, body weight was not significantly different
between the four groups. Plasma levels of glucose and insulin were
significantly increased in rats fed with 10% D-Glucose when
compared with age-matched control rats. Plasma glucose levels in
glucose-fed rats treated for 1 week with 10 mg/kg SSR240612
were not significantly different from control values. High plasma
insulin levels were significantly reduced in glucose-fed rats treated
with SSR240612 when compared with glucose-fed rats treated
with vehicle. Insulin resistance as assessed by the HOMA index
was increased by 5.6-fold in glucose-fed rats when compared with
age-matched control rats. This value was significantly reduced
though not completely normalised by one-week treatment with
SSR240612. The same regimen with SSR240612 failed to affect
plasma levels of glucose and insulin and the HOMA index in
control rats. Water intake was increased by 2-fold in glucose-fed
Figure 2. Effect of orally administered SSR240612 (10 mg/kg/day for 7 days) on systolic blood pressure in glucose-fed rats. From day
(D) 1 to 7, measurements were taken prior to the morning treatment with SSR240612. Data are mean 6 s.e.m of values obtained from (n) rats.
Statistical comparison with controls (*) or glucose-fed rats + vehicle ({) is indicated by ***{{{P, 0.001.
doi:10.1371/journal.pone.0012622.g002
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PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12622Figure 3. Effect of orally administered SSR240612 (10 mg/kg/day for 7 days) on (A) tactile allodynia and (B) cold allodynia in
glucose-fed rats. From day (D) 1 to 7, measurements were taken prior to the morning treatment with SSR240612. Data are mean 6 s.e.m of values
obtained from (n) rats. Statistical comparison with controls (*) or glucose-fed rats + vehicle ({) is indicated by {P, 0.05, {{P, 0.01, ***{{{P, 0.001.
doi:10.1371/journal.pone.0012622.g003
Table 2. Effects of SSR240612 (10 mg/kg/day 67 days) in rats treated with glucose.
Parameters
Control
n=6
Control + SSR240612
n=6
Glucose-fed + Vehicle
n=8
Glucose-fed + SSR240612
n=8
Body weight (g) 392.0612.3 397.265.9 408.467.3 387.6612.9
Plasma glucose (mmol/L) 5.860.2 6.360.2 7.860.8
* 6.660.4
Plasma insulin (ng/ml) 1.060.3 0.860.2 7.061.4
*** 2.160.3
** {{{
HOMA index 5.261.3 4.961.1 29.262.8
*** 10.461.8
* {{{
Drinking (ml) 58.262.2 59.761.2 119.165.0
** 112.668.5
**
Food intake (g) 30.960.2 30.660.2 20.761.1
** 22.560.8
**
Values represent the mean 6 s.e.m of (n) rats. Statistical comparison to control rats (*) or to glucose + vehicle (
{) is indicated by
* P,0.05;
** P,0.01;
*** {{{ P,0.001.
doi:10.1371/journal.pone.0012622.t002
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SSR240612 treatment for 7 days had no effect on drinking or
eating behaviour in both glucose-fed rats and controls rats
(Table 2).
Chronic effect of SSR240612 on B1R binding sites and B1R
mRNA in spinal cord
Quantitative autoradiography showed a significant increase of
specific density of kinin B1R binding sites through laminae I to X
of the thoracic spinal cord in glucose-fed rats when compared to
age-matched control spinal cord (Figure 4A and 4B). This
overexpression of B1R binding sites in glucose-fed rats was
significantly reduced in all laminae by the one-week treatment
with 10 mg/kg SSR240612. As shown in figure 4C, B1R mRNA
was underexpressed in the spinal cord of control rats. In glucose-
fed rats, however, B1R mRNA was increased by 80-fold. Again,
the overexpression of B1R mRNA in the spinal cord of glucose-fed
rats was significantly and markedly decreased by SSR240612.
Chronic effect of SSR240612 on B1R mRNA levels in
peripheral organs
Similarly to the spinal cord, levels of B1R mRNA were
relatively low in aorta, liver and gastrocnemius muscle of control
Figure 4. Effect of orally administered SSR240612 (10 mg/kg/day for 7 days) on B1R expression in the thoracic spinal cord. A:
Quantification of specific density of [
125I]-HPP-desArg
10-Hoe 140 to B1R in various spinal cord laminae (Lam). B: Autoradiograms of thoracic spinal cord for
B1R. The non-specific binding (NS) was obtained by the co-addition of 1 mMR - 7 1 5( B 1R antagonist)with[
125I]-HPP-desArg
10-Hoe 140.C: Bars represent fold
change in gene expression for B1R. Data are mean 6 s.e.m of values obtained from (n) rats. Statistical comparison with controls (*) or glucose-fed rats +
vehicle ({)i si n d i c a t e db y*P , 0.05, **{{P, 0.01, ***P, 0.001.
doi:10.1371/journal.pone.0012622.g004
Figure 5. B1R mRNA levels in aorta, liver and skeletal muscle
after orally administered SSR240612 (10 mg/kg/day for 7
days). Data are mean 6 s.e.m of values obtained from (n) rats.
Statistical comparison with controls (*) or glucose-fed rats + vehicle ({)
is indicated by { P, 0.05, {{P, 0.01, ***{{{P, 0.001.
doi:10.1371/journal.pone.0012622.g005
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were markedly and significantly upregulated in the same tissues.
The one-week treatment with 10 mg/kg SSR240612 reversed
completely B1R mRNA overexpression in aorta and skeletal
muscle and reduced significantly B1R mRNA level in the liver of
glucose-fed rats. The antagonist was without effect on the basal
expression of B1R mRNA in control rats.
Chronic effect of SSR240612 on oxidative stress
Effects of 8-week treatment with glucose on basal and NADPH-
stimulated O2
N2 production measured in the aorta using lucigenin-
enhanced chemiluminescence are shown in figure 6. Glucose feeding
resulted in a 1.9-fold increase of basal O2
N2 production in the aorta
when compared to control aorta (Figure 6A). The one-week
treatment with SSR240612 normalised the higher production of
O2
N2in glucose-fed rats to control levels.SSR240612 failed, however,
to alter basal O2
N2 production in the aorta of control rats (Figure 6A).
Moreover, NADPH oxidase activity was significantly increased by 2-
fold in the aorta of glucose-fed rats. Again, the increase of NADPH
oxidase activity in glucose-fed rats was significantly reduced by the
one-week treatment with SSR240612. The latter treatment with the
B1R antagonist failed to alter O2
N2 production induced by NADPH
in the aorta of control rats (Figure 6B).
The production of O2
N2 evaluated with the oxidative
fluorescent dye dihydroethidine was also markedly increased
in vascular smooth muscle cells of the aorta in glucose-fed rats
(Figures 7C and 8). Daily treatment with 10 mg/kg SSR240612
for a week abolished the fluorescent labelling seen in the aorta
of glucose-fed rats to control levels (Figures 7D and 8).
However, the weak labelling displayed in the aorta of control
rats was not affected by the B1R antagonist (Figures 7A-B
and 8).
Pro-oxidative effect of B1R
To further substantiate the contribution of B1R in the
production of O2
N2, aortas from glucose-fed rats were incubated
in the presence of the B1R agonist Sar[D-Phe8]des-Arg9-BK
(20 mM). Results presented in figure 9 show that the B1R agonist
Figure 6. Effect of orally administered SSR240612 (10 mg/kg/day for 7 days) on oxidative stress. (A) Basal superoxide anion production,
(B) NADPH oxidase activity in the aorta of glucose-fed rats. Data are mean 6 s.e.m of values obtained from (n) rats. Statistical comparison with
controls (*) or glucose-fed rats + vehicle ({) is indicated by **{{P, 0.01, ***{{{P, 0.001.
doi:10.1371/journal.pone.0012622.g006
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N2. Whereas the pro-
oxidative response to Sar[D-Phe8]des-Arg9-BK was not signifi-
cantly affected by allopurinol (xanthine oxidase inhibitor) and L-
NAME (a non-selective inhibitor of all NOS isoforms), it was
completely blocked by apocynin (NADPH oxidase inhibitor).
Baseline values of O2
N2 production in glucose-treated aortas were
either slightly reduced (L-NAME) or normalized (apocynin and
allopurinol) by these inhibitors.
The intraperitoneal administration of Sar[D-Phe8]des-Arg9-BK
(1 mg/kg) in 8-week glucose-fed rats also enhanced by 4-fold the
production of O2
N2 in aorta (Figure 10). Similarly to the in vitro
protocol, systemic treatment with apocynin (50 mg/kg) abolished
the effect of the B1R agonist on the production of O2
N2. It is worth
mentioning that apocynin normalized the increasing effect of
glucose on baseline O2
N2 production. These findings suggest that
B1R activation can increase the production of superoxide anion
primarily through NADPH oxidase.
Chronic effect of SSR240612 on superoxide dismutase
and catalase expression
The impact of SSR240612 was evaluated on the vascular
antioxidant defence. Firstly, the mRNA and protein expressions of
MnSOD were markedly increased in the aorta of glucose-fed rats
when compared to age-matched control rats (Figure 11A and
11B). The up-regulation of this antioxidant enzyme was reversed
(mRNA) or significantly reduced (protein) by the one-week
treatment with 10 mg/kg SSR240612. Secondly, the protein
expression of catalase was significantly increased in the aorta of 8-
week glucose-fed rats and the one-week treatment with
SSR240612 reduced it significantly (Figure 12). In contrast, the
prolonged treatment with the B1R antagonist had no significant
effect on MnSOD or catalase expression in the aorta of control
rats (Figures 11–12).
Discussion
This study provides the first demonstration that the activation of
B1R increased the oxidative stress through the activation of
NADPH oxidase in the vasculature and that the sustained
inhibition of B1R for one-week with SSR240612 reversed the
oxidative stress and the subsequent B1R upregulation in a model of
insulin resistance. Indeed, activation of B1R with a selective
agonist either in vitro or in vivo enhanced the production of aortic
superoxide anion which was abolished by apocynin, a selective
inhibitor of NADPH oxidase. The inhibition of B1R had positive
outcome on diabetic complications in the model of glucose-fed rat.
Figure 7. Superoxide anion production on histological sections of the aorta marked with dihydroethidine. Control (A, B) and glucose-
treated rats (C, D) after 7-day treatment with Vehicle (A, C) or 10 mg/kg/day SSR240612 (B, D). Asterisk (*) indicates the lumen side of the section. The
arrow (in A) represents the elastic lamina of the smooth muscle cells while the two arrows (in C) show the increase of fluorescent ethidium bromide in
the nucleus of smooth muscle cells in the aorta of glucose-treated rat. The fluorescent marker is reduced after treatment with SSR240612 (in D). Scale
bar is 20 mm in each panel. Images are representative of 4 aortas in each group.
doi:10.1371/journal.pone.0012622.g007
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in both control and glucose-fed rats, excluding an indirect effect of
the drug on glucose intake.
Our findings on B1R-induced allodynia are in keeping with the
role of B1R in hyperalgesia in inflammatory, diabetic and painful
processes [27,28,29] and with the therapeutic effect of SSR240612
in neuropathic and inflammatory pain [12,30].
Relationship between oxidative stress, B1R and glucose-
induced hypertension and allodynia
It is known that diets containing high refined carbohydrates
such as fructose, sucrose and glucose elevate blood pressure in rats
[10,31,32,33]. Simple carbohydrate feeding to rat and high
glucose infusion for 2 days elevate reactive oxygen species (ROS)
[9,34,35]. Increased production of O2
N2 is correlated with high
blood pressure in glucose-fed rats [8,9]. Alpha-lipoic acid
attenuates aortic and heart mitochondrial O2
N2 production in
glucose-fed rats [7,10] and reverses hypertension in fructose and
glucose-fed rats [2,10,36]. The antioxidant N-acetyl-L-cysteine
Figure 9. Effects of in vitro B1R activation on superoxide anion production in the aorta of glucose-fed rats pre-treated or not with
oxidative enzyme inhibitors. Basal and stimulated production of superoxide anion in the presence of the B1R agonist Sar[D-Phe
8]des-Arg
9-BK
(20 mM) were measured in the presence of (A) Allopurinol (xanthine oxidase inhibitor), (B) L-NAME (inhibitor of all NOS isoforms) and (C) Apocynin
(NADPH oxidase inhibitor) at the indicated concentrations (see methods). Data are mean 6 s.e.m of values obtained from (n) rats. Statistical
comparison with control (*), glucose (+) or Sar[D-Phe
8]des-Arg
9-BK ({) is indicated by *
+ P, 0.05, **
++ {{P, 0.01.
doi:10.1371/journal.pone.0012622.g009
Figure 8. Fluorescence intensities of superoxide (dihydroethi-
dium) staining in aortic sections from control and 8-week
glucose-treated rats shown in Figure 7. Data are expressed as
fluorescence intensity in arbitrary unit (a.u.) and represent the mean 6
s.e.m of 4 rats in each group. Statistical comparison with controls (*) or
glucose-fed rats + vehicle ({) is indicated by ***{{{P, 0.001.
doi:10.1371/journal.pone.0012622.g008
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the NADPH oxidase inhibitor. Basal and stimulated production of superoxide anion with the B1R agonist Sar[D-Phe
8]des-Arg
9-BK (1 mg/kg, i.p.).
Apocynin (50 mg/kg, i.p.) was administered 30 min prior to the B1R agonist (see methods). Data are mean 6 s.e.m of values obtained from (n) rats.
Statistical comparison with glucose (+) or Sar[D-Phe
8]des-Arg
9-BK ({) is indicated by
+ P, 0.05,
++ {{P, 0.01,
+++P, 0.001.
doi:10.1371/journal.pone.0012622.g010
Figure 11. Effect of orally administered SSR240612 (10 mg/kg/day for 7 days) on vascular expression of superoxide dismutase. The
expression of MnSOD was measured at (A) mRNA level by qRT-PCR, and (B) at protein level by Western blot in the aorta of glucose-fed rats. Data are
mean 6 s.e.m of values obtained from (n) rats. Statistical comparison with controls (*) or glucose-fed rats + vehicle ({) is indicated by *
{P, 0.05,
{{P,
0.01.
doi:10.1371/journal.pone.0012622.g011
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rats [3,37].
It is also well established that increased oxidative stress causes
diabetic neuropathy, especially through the polyol pathway (high
activity of the aldose reductase). Hyperglycemia induces nerve loss
and reduces nerve velocity through oxidative stress. These
problems are alleviated by alpha-lipoic acid [38]. In our model
of high glucose feeding, alpha-lipoic acid and N-acetyl-L-cysteine
were able to reduce simultaneously vascular oxidative stress, B1R
upregulation, hypertension and allodynia [2,3,7]. This is consistent
with the increased B1R mRNA and protein expression following a
12 h exposure of mesenteric vascular endothelial cells with 25 mM
glucose [39]. The corollary of these findings is that the oxidative
stress is likely the primary mechanism involved in the induction of
B1R in the model of insulin resistance induced by high glucose
intake. The oxidative stress can activate the nuclear factor kappa B
(NF-kB) pathway [40,41] which is directly involved in the
upregulation of B1R [4]. B1R may therefore represent a molecular
marker of the oxidative stress.
Source of superoxide anion and pro-oxidative effect of
B1R in glucose-fed rats
The NADPH oxidase is a predominant source of ROS
production (O2
N2) in cardiovascular tissues in response to high
glucose, growth factors and vasoactive peptides [42,43,44].
NADPH oxidase activity and O2
N2 levels were increased in
cultured vascular smooth muscle cells exposed to high glucose
concentration [45], in animal and clinical models of hypertension
and diabetes [42,44,46]. In our study, the complete inhibition of
increased glucose-induced superoxide anion by apocynin con-
firmed the predominant contribution of NADPH oxidase.
However, the complete inhibition O2
N2 levels with allopurinol
and its partial inhibition with L-NAME suggest multiple sources of
ROS in this model, including xanthine oxidase and uncoupling
eNOS. Xanthine oxidase was also proposed as a source of ROS in
the vasculature in models of hypertension [42]. Furthermore, the
increased NADPH activity observed in the present study is in
agreement with data reported in the aorta of db/db mice, a type 2
model of diabetes [46].
A key finding of the present study was the demonstration that a
one-week treatment with SSR240612 reversed the vascular
oxidative stress and normalized B1R up-regulation in glucose-fed
rats. This contrasts with the acute treatment with SSR240612
which did not affect O2
N2 production in aorta [1]. The inhibition
of NADPH oxidase activity may represent a molecular mechanism
by which SSR240612 reduces the oxidative stress. This statement
is supported by the increased production of O2
N2 by the B1R
agonist in isolated aorta of glucose-fed rats, whose effect was
sensitive to the NADPH oxidase inhibitor apocynin. This
observation was confirmed in aorta isolated from glucose-fed rats
treated in vivo with apocynin prior to the B1R agonist. Xanthine
oxidase and uncoupling eNOS are unlikely involved in O2
N2
production by the B1R agonist since their respective inhibitors
(allopurinol and L-NAME) did not affect significantly the pro-
oxidative effect of the B1R agonist despite they reduced glucose-
induced oxidative stress. Thus the inhibition of the oxidative stress
by SSR240612 is likely due to the inhibition of the NADPH
dependent pro-oxidative effect of B1R activation. The inhibition
and down-regulation of B1R-induced oxidative stress following
chronically administered SSR240612 may explain the persistent
normalization of high blood pressure, allodynia and insulin
resistance in glucose-fed rats.
Antioxidant defence and SSR240612
It is generally believed that the exposure of cells to oxidative
stress is associated with increased antioxidant enzyme activity [47].
Exposure of human endothelial cells to 20 mM glucose for 1–2
weeks increased mRNA expression of CuZnSOD and MnSOD
[48]. Likewise, porcine aortic vascular smooth muscle cells
cultured in 25 mM glucose for 10 days increased MnSOD mRNA
expression [49]. SOD activity was similarly increased in the
plasma of 3-week glucose-fed rats [10]. Moreover, SOD and
catalase activity were significantly increased during the early stage
of diabetes in streptozotocin-treated rats [50]. Thus, the increased
expression of MnSOD and catalase in the aorta of 8-week glucose-
fed rats is congruent with previous studies and may reflect a
compensatory mechanism to the enhanced oxidative stress in
glucose-fed rats. It is therefore logical that the reduction of the
oxidative stress by chronic treatment with B1R antagonist resulted
in a normalization of the MnSOD and catalase expression. This
further links B1R to the generation of the oxidative stress and
suggests that the inhibitory effect of SSR240612 on the
antioxidant defence is indirect and likely due to the inhibition of
the production of ROS.
Link between B1R and angiotensin II (ANG II)
Endogenous ANG II was found to enhance B1R expression via
AT1 receptor in endothelium of small cardiac arteries and
cardiomyocytes in two-kidney-one-clip hypertensive rats [51].
Also the experimental model of hypertension induced by chronic
infusion of ANG II induced B1R expression in rat aorta [52] and
spinal cord [53] as previously shown in cultured vascular smooth
muscle [54] through a mechanism associated with the oxidative
stress and NF-kB. ANG II can activate NF-kB through increases of
vascular superoxide production following membrane NADPH
oxidase activation [55,56]. NF-kB is the transcription factor that
allows the increased expression of B1R [57]. Likewise the model of
Figure 12. Effect of orally administered SSR240612 (10 mg/kg/
day for 7 days) on vascular expression of catalase. The
expression of catalase was measured at protein level by Western blot
in the aorta of glucose-fed rats. Data are mean 6 s.e.m of values
obtained from (n) rats. Statistical comparison with controls (*) or
glucose-fed rats + vehicle ({) is indicated by
{P, 0.05,
**P, 0.01.
doi:10.1371/journal.pone.0012622.g012
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effect of SSR240612 was recently demonstrated in ANG II-
hypertensive rats and spontaneously hypertensive rats [58].
Putative role of B2R and its relationship with B1R
expression
Acute treatment with the B2R antagonist Icatibant (1 mg/kg)
reversed allodynia but not hypertension in rats treated with D-
glucose for 12 weeks [59]. Further studies are, however, necessary
to determine the influence of B2R on the oxidative stress-induced
pathological changes in this model. In addition to its pro-
nociceptive and pro-inflammatory effects, increasing evidence
shows that the B2R is nephro- and cardioprotective
[60,61,62,63,64,65], partly due to nitric oxide (NO) release, and
could contribute to the benefit of angiotensin 1-converting enzyme
(ACE) inhibitors in models of diabetes and cardiovascular diseases
[5,60,66,67].
Whereas the B1R is associated with leptin resistance and obesity
[13], its beneficial or detrimental role in cardiac ischemia remains
conflicting [65,68,69,70] and recently, B1R was found implicated
in renal fibrosis [71]. The lack of both kinin B1R and B2R
enhances diabetic complications, including nephropathy and
neuropathy in Akita diabetic mice [64]. In addition, genetically
diabetic mice that lack the B2R develop a more severe kidney
pathology by age 6 months and develop senescence-associated
phenotypes by age 12 months [72,73]. However, the expression of
B1R is markedly enhanced in B2R knockout mice [72,74]. Renal
expression of B2R is also significantly enhanced in B1R knockout
mice [75], suggesting that the absence of one kinin receptor is
compensated by the over-expression of the remaining kinin
receptor. Thus, investigation on the respective role of B1R and
B2R in diabetes using genetically modified mice must be cautiously
interpreted since it does not simply reflect the absence of a given
receptor and may explain apparent contradiction with pharma-
cological studies. Furthermore, other important genes are affected
by genetic deletion of either kinin receptor. For instance, genetic
disruption of B1Ro rB 2R and both receptors decreased ACE and
ANG II AT1R function and expression in mice abdominal aorta,
indicating that kinin receptors regulate AT1 receptors and ACE
[76,77]. Moreover, B2R knockout mice have increased ANG II
AT2R mRNA and protein expression that contributes to elevation
of NO as compensatory protective mechanism in thrombosis [78].
Finally, our study addressed the role of B1R in insulin resistance
which corresponds to the early phase of diabetes. The therapy with
B1R antagonists in a more advanced phase of diabetes as in Akita
diabetic mice remains to be clarified.
Conclusion
The present study provides the first evidence that the B1R can
perpetuate the oxidative stress by increasing the production of
superoxide anion following the activation of NADPH oxidase in a
model of insulin resistance. Prolonged inhibition of B1R with
SSR240612 reversed hypertension, pain polyneuropathy and
metabolic alterations in glucose-fed rats. Part of the beneficial
effects of SSR240612 appears to be associated with the
normalization of B1R gene and protein expression which is
dependent on the oxidative stress.
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